CliffBio
biologic

Skyrizi

risankizumab-rzaa

Loss of exclusivity—loss of exclusivity
CompanyAbbVie Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameSkyrizi
Active ingredientrisankizumab-rzaa
Strength360MG/2.4ML (150MG/ML)
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
Marketing statusRx

More from AbbVie Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.